Featured Research

from universities, journals, and other organizations

Melanoma Treatment Options One Step Closer

Date:
October 20, 2009
Source:
University of Alberta
Summary:
A targeted chemotherapy for the treatment of skin cancer is one step closer, after researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.

A targeted chemotherapy for the treatment of skin cancer is one step closer, after a team of University of Alberta researchers successfully synthesized a natural substance that shows exceptional potential to specifically treat this often fatal disease.

U of A chemistry professor Dennis Hall said after three years of work, his research team has successfully produced the substance called Palmerolide A.

"The potency of palmerolide is exceptional and melanoma is a very aggressive cancer for which there is almost no chemotherapeutic recourse," said Hall. "Natural substances like palmerolide offer real hope for such treatments.

"Current chemotherapy as an overall strategy is not very effective in treating melanoma. Less than a quarter of patients respond to chemotherapy and it typically only works for less than a year, and it has little to no effect on survival time. Palmerolide A as a targeted therapy may prove to be more effective [for treatment] with less toxicity," said Hall.

"One of the problems with most cancer drugs is the lack of selectivity for cancer cells versus normal cells. Preliminary data for Palmerolide A looks very promising in terms of solving this issue," he said.

"For commercialization, the structure needs to be made more 'drug-like;' smaller and more water-soluble, while preserving the potency," said Hall, who is optimistic that his U of A team is moving forward in the race to develop a treatment for melanoma.

Hall's research findings were recently published in the Journal of the American Chemical Society.


Story Source:

The above story is based on materials provided by University of Alberta. Note: Materials may be edited for content and length.


Cite This Page:

University of Alberta. "Melanoma Treatment Options One Step Closer." ScienceDaily. ScienceDaily, 20 October 2009. <www.sciencedaily.com/releases/2009/10/091020122534.htm>.
University of Alberta. (2009, October 20). Melanoma Treatment Options One Step Closer. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/10/091020122534.htm
University of Alberta. "Melanoma Treatment Options One Step Closer." ScienceDaily. www.sciencedaily.com/releases/2009/10/091020122534.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins